TY - JOUR AB - Cardiac fibrosis is a hallmark of cardiac remodeling associated with nearly all forms of heart disease. Clinically, no effective therapeutic drugs aim to inhibit cardiac fibrosis, owing to the complex etiological heterogeneity and pathogenesis of this disease. A two‑in‑one protein structure, a ubiquitous expression profile and unique biophysical characteristics enable the involvement of transient receptor potential melastatin‑subfamily member 7 (TRPM7) in the pathogenesis and development of fibrosis‑related cardiac diseases, such as heart failure (HF), cardiomyopathies, arrhythmia and hyperaldosteronism. In response to a variety of stimuli, multiple bioactive molecules can activate TRPM7 and related signaling pathways, leading to fibroblast proliferation, differentiation and extracellular matrix production in cardiac fibroblasts. TRPM7‑mediated Ca2+ signaling and TGF‑β1 signaling pathways are critical for the formation of fibrosis. Accumulating evidence has demonstrated that TRPM7 is a potential pharmacological target for halting the development of fibrotic cardiac diseases. Reliable drug‑like molecules for further development of high‑affinity in vivo drugs targeting TRPM7 are urgently needed. The present review discusses the widespread and significant role of TRPM7 in cardiac fibrosis and focuses on its potential as a therapeutic target for alleviating heart fibrogenesis. AD - Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China Department of Laboratory Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China Department of Cardiology, The Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China Department of Medical Education, The Second Clinical Medical College of Nanchang University, Nanchang, Jiangxi 330006, P.R. China Department of Pharmacy, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China AU - Hu,Feng AU - Li,Meiyong AU - Han,Fengyu AU - Zhang,Qing AU - Zeng,Yuhao AU - Zhang,Weifang AU - Cheng,Xiaoshu DA - 2021/02/01 DO - 10.3892/etm.2020.9604 IS - 2 JO - Exp Ther Med KW - cardiac fibrosis cardiac remodeling transient receptor potential melastatin‑subfamily member 7 PY - 2021 SN - 1792-0981 1792-1015 SP - 173 ST - Role of TRPM7 in cardiac fibrosis: A potential therapeutic target (Review) T2 - Experimental and Therapeutic Medicine TI - Role of TRPM7 in cardiac fibrosis: A potential therapeutic target (Review) UR - https://doi.org/10.3892/etm.2020.9604 VL - 21 ER -